Literature DB >> 24385293

Age-related decline in dopamine transporter in human brain using PET with a new radioligand [¹⁸F]FE-PE2I.

Yoshitoshi Shingai1, Amane Tateno, Ryosuke Arakawa, Takeshi Sakayori, WooChan Kim, Hidenori Suzuki, Yoshiro Okubo.   

Abstract

OBJECTIVE: Dopamine transporter (DAT) density is considered as a marker of pre-synaptic function. Numerous neuroimaging studies have consistently demonstrated an age-related decrease in DAT density in normal human brain. However, the precise degree of the regional decline is not yet clear. The purpose of this study was to evaluate the effect of the normal aging process on DAT densities in human-specific brain regions including the substantia nigra and thalamus using positron emission tomography (PET) with [(18)F]FE-PE2I, a new PET radioligand with high affinity and selectivity for DAT.
METHODS: Thirty-six healthy volunteers ranging in age from 22 to 80 years were scanned with PET employing [(18)F]FE-PE2I for measuring DAT densities. Region of interest (ROI)-based analysis was used, and ROIs were manually defined for the caudate, putamen, substantia nigra, thalamus, and cerebellar cortex. DAT binding was quantified using a simplified reference tissue model, and the cerebellum was used as reference region. Estimations of binding potential in the caudate, putamen, substantia nigra, and thalamus were individually regressed according to age using simple regression analysis. Estimates of DAT loss per decade were obtained using the values from the regression slopes.
RESULTS: There were 7.6, 7.7, and 3.4% per-decade declines in DAT in the caudate, putamen, and substantia nigra, respectively. By contrast, there was no age-related decline of DAT in the thalamus.
CONCLUSIONS: [(18)F]FE-PE2I allowed reliable quantification of DAT, not only in the caudate and putamen but also in the substantia nigra. From the results, we demonstrated the age-related decline in the caudate and putamen as reported in previous studies, and additionally for those in the substantia nigra for the first time.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24385293     DOI: 10.1007/s12149-013-0798-1

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  12 in total

1.  Dopaminergic control of anxiety in young and aged zebrafish.

Authors:  Victoria Kacprzak; Neil A Patel; Elizabeth Riley; Lili Yu; Jing-Ruey J Yeh; Irina V Zhdanova
Journal:  Pharmacol Biochem Behav       Date:  2017-04-10       Impact factor: 3.533

2.  Development of a clinically feasible [11C]PE2I PET method for differential diagnosis of parkinsonism using reduced scan duration and automated reference region extraction.

Authors:  My Jonasson; Lieuwe Appel; Torsten Danfors; Dag Nyholm; Håkan Askmark; Andreas Frick; Jonas Engman; Tomas Furmark; Jens Sörensen; Mark Lubberink
Journal:  Am J Nucl Med Mol Imaging       Date:  2017-12-20

3.  Relationship between neuromelanin and dopamine terminals within the Parkinson's nigrostriatal system.

Authors:  Antonio Martín-Bastida; Nicholas P Lao-Kaim; Andreas Antonios Roussakis; Graham E Searle; Yue Xing; Roger N Gunn; Stefan T Schwarz; Roger A Barker; Dorothee P Auer; Paola Piccini
Journal:  Brain       Date:  2019-07-01       Impact factor: 13.501

4.  Effect of sex on aging-related decline of dopamine transporter in healthy subjects.

Authors:  Seunghyeon Shin; Hyun-Yeol Nam; Myung Jun Lee; Kyoungjune Pak; Keunyoung Kim; In Joo Kim
Journal:  Ann Nucl Med       Date:  2020-10-14       Impact factor: 2.668

5.  The Effects of Age, from Young to Middle Adulthood, and Gender on Resting State Functional Connectivity of the Dopaminergic Midbrain.

Authors:  Andrew C Peterson; Sheng Zhang; Sien Hu; Herta H Chao; Chiang-Shan R Li
Journal:  Front Hum Neurosci       Date:  2017-02-07       Impact factor: 3.169

6.  Ventral striatal dopamine transporter availability is associated with lower trait motor impulsivity in healthy adults.

Authors:  Christopher T Smith; M Danica San Juan; Linh C Dang; Daniel T Katz; Scott F Perkins; Leah L Burgess; Ronald L Cowan; H Charles Manning; Michael L Nickels; Daniel O Claassen; Gregory R Samanez-Larkin; David H Zald
Journal:  Transl Psychiatry       Date:  2018-12-07       Impact factor: 6.222

7.  Dopamine Transporter Density in de novo Parkinson's Disease Does Not Relate to the Development of Levodopa-Induced Dyskinesias.

Authors:  Andreas-Antonios Roussakis; Marta Gennaro; Nicholas P Lao-Kaim; David Towey; Paola Piccini
Journal:  J Neuroinflamm Neurodegener Dis       Date:  2019-06-05

8.  99mTc-TRODAT-1 SPECT Revealed That Striatal Dopamine Transport Availability Significantly Decreases in Late Mid-Aged Healthy Taiwanese and Then Remains Stable.

Authors:  Skye Hsin-Hsien Yeh; Chi-Jung Tsai; Tsung-Hsun Yu; Yung-Hsiao Chiang; Shinn-Zong Lin; Nan-Jing Peng; Wen-Sheng Huang
Journal:  Clin Nucl Med       Date:  2022-03-01       Impact factor: 7.794

9.  A candidate gene investigation of methylphenidate response in adult attention-deficit/hyperactivity disorder patients: results from a naturalistic study.

Authors:  Tor-Arne Hegvik; Kaya Kvarme Jacobsen; Mats Fredriksen; Tetyana Zayats; Jan Haavik
Journal:  J Neural Transm (Vienna)       Date:  2016-04-18       Impact factor: 3.575

10.  Dopamine transporter imaging with [18F]FE-PE2I PET and [123I]FP-CIT SPECT-a clinical comparison.

Authors:  Susanna Jakobson Mo; Jan Axelsson; Lars Jonasson; Anne Larsson; Mattias J Ögren; Margareta Ögren; Andrea Varrone; Linda Eriksson; David Bäckström; Sara Af Bjerkén; Jan Linder; Katrine Riklund
Journal:  EJNMMI Res       Date:  2018-11-15       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.